BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
MENLO PARK, Calif., Feb. 07, 2017 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 10:30 AM EST and at the LEERINK Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 2:30 PM EST.
Audio webcasts of Corium’s presentations may be accessed by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com. The webcasts will be archived on the Corium website for two weeks following the presentations.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma, Endo Pharmaceuticals and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan M. Pietropaolo [email protected] (201) 923-2049
